Aquestive Therapeutics, Inc. AQST Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s business segments — R&D?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — R&D of $4.2M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — R&D decreased by 21.6% year-over-year, from $5.36M to $4.2M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — R&D?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — R&D has grown at a 14.5% compound annual growth rate (CAGR), from $13.1M to $17.19M.
- What does business segments — R&D mean?
- Captures the expenditures dedicated to the discovery, clinical development, and regulatory advancement of the segment's pharmaceutical pipeline. This investment is critical for long-term value creation and future product commercialization. It reflects the company's commitment to innovation and its strategic focus on addressing unmet medical needs.